Can there be consensus on whether vasectomy is a prostate cancer risk factor?

M. Minhaj Siddiqui,Edward L. Giovannucci,Lorelei A. Mucci

DOI: https://doi.org/10.1038/s41391-021-00400-w

2021-06-09

Prostate Cancer and Prostatic Diseases

Abstract:Prostate Cancer and Prostatic Diseases, Published online: 09 June 2021; doi:10.1038/s41391-021-00400-wCan there be consensus on whether vasectomy is a prostate cancer risk factor?

oncology,urology & nephrology

What problem does this paper attempt to address?

Vasectomy: potential links to an increased risk of aggressive prostate cancer?

Alexis R Gaines,Adriana C Vidal,Stephen J Freedland

DOI: https://doi.org/10.1586/14737140.2015.1086648

2015-09-07

Expert Review of Anticancer Therapy

Abstract:Several studies have found associations between aggressive prostate cancer (PC) and having a vasectomy. However, findings from two very recent meta-analyses have found that this is not the case. Therefore, the data are mixed. Herein, we detail the controversy between vasectomy and PC risk, particularly aggressive PC, by shedding some light on the molecular pathways, potential risk factors and suggested links for those considering vasectomy and medical professionals who perform it. We conclude by supporting the American Urological Association's position that there is no need to discuss potential prostate cancer risks with patients considering vasectomy given reasonably strong data finding no link between vasectomy and prostate cancer risk.

oncology
Vasectomy and prostate cancer risk: a meta-analysis of prospective studies

Sheng Cheng,Bo Yang,Liwei Xu,Qiming Zheng,Guoqing Ding,Gonghui Li

DOI: https://doi.org/10.1093/carcin/bgaa086

2021-02-11

Carcinogenesis

Abstract:Epidemiological cohort studies investigating the association between vasectomy and prostate cancer risk have yielded inconsistent results. The aim of the present meta-analysis is to update the evidence on the association between vasectomy and prostate cancer. A comprehensively literature search of relevant studies was performed in December 2019 using PubMed. A DerSimonian and Laird random-effects model was used to calculate the summary relative risk (RR) and its 95% confidence interval (CI). A total of 15 eligible cohort studies (16 data sets) with more than four million of participants were eventually included in this meta-analysis. There was a statistically significant higher risk of prostate cancer among men who underwent vasectomy (RR: 1.09, 95% CI: 1.04-1.13) with obvious heterogeneity among included studies (P < 0.001, I2 = 64.2%). Vasectomy was also associated with the risk of advanced prostate cancer (RR: 1.07, 95% CI: 1.02-1.13), which is less likely to be affected from detection bias. In conclusion, findings from this meta-analysis of prospective studies indicate that vasectomy may be positively associated with the risk of prostate cancer. Further large prospective studies with long follow-up are warranted to verify the findings from this meta-analysis. In addition, the potential underlying molecular mechanism needed further exploration with in vitro and animal studies.
Association between vasectomy and risk of prostate cancer: a meta-analysis

Yawei Xu,Lei Li,Wuping Yang,Kenan Zhang,Kaifang Ma,Haibiao Xie,Jingcheng Zhou,Lin Cai,Yanqing Gong,Zheng Zhang,Kan Gong

DOI: https://doi.org/10.1038/s41391-021-00368-7

Abstract:Background: The debate over the association between vasectomy and prostate cancer has been lasted about 40 years and there is no sign of stopping. In the present study, we aimed to evaluate whether vasectomy is associated with prostate cancer based on the most comprehensive and up-to-date evidence available. Methods: The PubMed, Cochrane Library, and EMBASE databases were systematically searched inception to March 14, 2021 without year or language restriction. Multivariable adjusted risk ratios (RRs) were used to assess each endpoint. Risk of bias was assessed using the Newcastle-Ottawa scale. Results: A total of 58 studies involving 16,989,237 participants fulfilled inclusion criteria. There was significant association of vasectomy with risk of any prostate cancer (risk ratio, 1.18, 95% CI, 1.07-1.31). Association between vasectomy and advanced prostate cancer (risk ratio, 1.06, 95% CI, 1.01-1.12), low-grade prostate cancer (risk ratio, 1.06, 95% CI, 1.02-1.10), and intermediate-grade prostate cancer (risk ratio, 1.12, 95% CI, 1.03-1.22) were significant. There was no significant association between vasectomy and prostate cancer-specific mortality (risk ratio, 1.01, 95% CI, 0.93-1.10). Conclusions: This study found that vasectomy was associated with the risk of any prostate cancer and advanced prostate cancer. From the current evidence, patients should be fully informed of the risk of prostate cancer before vasectomy.
Vasectomy and prostate cancer risk: a meta-analysis of cohort studies

Yonggang Shang,Guangwei Han,Jia Li,Jiang Zhao,Dong Cui,Chengcheng Liu,Shanhong Yi

DOI: https://doi.org/10.1038/srep09920

2015-04-30

Abstract:Some studies have suggested that vasectomy is associated with the increased risk of prostate cancer, however, this conclusion is not supported by all the published studies. In order to examine the relationship between vasectomy and prostate cancer risk, we conducted a meta-analysis of cohort studies to clarify this controversial association. PubMed and Medline were used to identify the cohort studies that reported the association of vasectomy with prostate cancer risk from 1980 to January 2015. Based on a random effects model, the RR and 95% CI were used to assess the combined risk. In total, 10 cohort studies involving more than 7027 cases and 429914 participants were included. There was no significant relationship between vasectomy and prostate cancer risk, the pooled RR (95%CI) was 1.11[0.98, 1.27] (P = 0.109). In subgroup-analysis, the relationship between vasectomy and prostate cancer risk was not significantly modified by the length of follow-up and population distribution except Americans. Omission of any single study had little effect on the pooled risk estimate. Little evidence of publication bias was found. In conclusion, our meta-analysis suggests that vasectomy is not associated with the increased risk of prostate cancer. More studies based on other populations including the Chinese are needed.
Vasectomy and the risk of prostate cancer: a meta-analysis of cohort studies

Xiao-Long Zhang,Jia-Jun Yan,Shou-Hua Pan,Jian-Gang Pan,Xiang-Rong Ying,Guan-Fu Zhang

2015-10-15

Abstract:Background: The relationship of vasectomy to prostate cancer has great public health significance. However, the results of observational studies were conflicting. To determine whether vasectomy is associated with the risk of prostate cancer, we performed a meta-analysis of cohort studies. Methods: A literature search was carried out using Pubmed, Embase, Cochrane Libraryl, and China National Knowledge Infrastructure (CNKI) between January 1966 and July 2013. Before meta-analysis, between-study heterogeneity and publication bias were assessed using adequate statistical tests. Fixed-effect and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Potential sources of heterogeneity were detected by meta-regression. Subgroup analyses and sensitivity analysis were also performed. Results: A total of nine cohort studies contributed to the analysis. There was heterogeneity among the studies but no publication bias. Pooled results indicated that vasectomy was not associated with a significant increase of total prostate cancer risk (RR = 1.07, 95% CI [0.79, 1.46]). When stratified the various studies by geographic location, we found a significant association between vasectomy and increased PCa risk among studies conducted in the USA (RR = 1.54, 95% CI [1.23, 1.93]), however, there was no significant association between vasectomy and PCa risk among studies conducted in non-USA countries (RR = 0.74, 95% CI [0.50, 1.09]). Furthermore, sensitivity analysis confirmed the stability of the results. Conclusions: In conclusion, the present meta-analysis of cohort studies suggested that vasectomy was not associated with increased risk of prostate cancer. More in-depth studies are warranted to report more detailed results, including stratified results by age at vasectomy, tumor grade, and tumor stage.
Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study

Mohummad Minhaj Siddiqui,Kathryn M Wilson,Mara M Epstein,Jennifer R Rider,Neil E Martin,Meir J Stampfer,Edward L Giovannucci,Lorelei A Mucci

DOI: https://doi.org/10.1200/JCO.2013.54.8446

2014-09-20

Abstract:Purpose: Conflicting reports remain regarding the association between vasectomy, a common form of male contraception in the United States, and prostate cancer risk. We examined prospectively this association with extended follow-up and an emphasis on advanced and lethal disease. Patients and methods: Among 49,405 U.S. men in the Health Professionals Follow-Up Study, age 40 to 75 years at baseline in 1986, 6,023 patients with prostate cancer were diagnosed during the follow-up to 2010, including 811 lethal cases. In total, 12,321 men (25%) had vasectomies. We used Cox proportional hazards models to estimate the relative risk (RR) and 95% CIs of total, advanced, high-grade, and lethal disease, with adjustment for a variety of possible confounders. Results: Vasectomy was associated with a small increased risk of prostate cancer overall (RR, 1.10; 95% CI, 1.04 to 1.17). Risk was elevated for high-grade (Gleason score 8 to 10; RR, 1.22; 95% CI, 1.03 to 1.45) and lethal disease (death or distant metastasis; RR, 1.19; 95% CI, 1.00 to 1.43). Among a subcohort of men receiving regular prostate-specific antigen screening, the association with lethal cancer was stronger (RR, 1.56; 95% CI, 1.03 to 2.36). Vasectomy was not associated with the risk of low-grade or localized disease. Additional analyses suggested that the associations were not driven by differences in sex hormone levels, sexually transmitted infections, or cancer treatment. Conclusion: Our data support the hypothesis that vasectomy is associated with a modest increased incidence of lethal prostate cancer. The results do not appear to be due to detection bias, and confounding by infections or cancer treatment is unlikely.
Vasectomy and risk of prostate cancer: a systematic review and meta-analysis of cohort studies

L H Liu,R Kang,J He,S K Zhao,F T Li,S P Wan,Z G Zhao

DOI: https://doi.org/10.1111/andr.12040

Andrology

Abstract:The results of published literature focusing on the association between vasectomy and the incidence of prostate cancer are often inconsistent. We conducted a meta-analysis to provide a quantitative assessment of the association between vasectomy and the risk of prostate cancer. We identified all cohort studies by searching the PubMed, Embase, and Cochrane Library before August 2014. The quality of the studies was evaluated using the Newcastle-Ottawa Scale checklist. Summary effect estimates with 95% confidence intervals (CI) were derived using a fixed or random effects model, depending on the heterogeneity of the included studies. Nine cohort studies that spanned across two continents involving 1 127 096 participants (ages 20-75) with 7539 cases of prostate cancer cases were included in the meta-analysis. The overall combined relative risks for men with the reference group were 1.08 (95% CI: 0.87-1.34) in a random effects, however, the association was not statistically significant (p = 0.48). Estimates of total effects were generally consistent in the sensitivity and subgroup analyses. No evidence of publication bias was observed. This meta-analysis indicated that vasectomy may not contribute to the risk of prostate cancer. The conclusion might have a far-reaching significance for the public health, especially in countries with high prevalence rates of vasectomy.
Vasectomy and prostate cancer risk: a historical synopsis of undulating false causality

Max Nutt,Zachary Reed,Tobias S Köhler

DOI: https://doi.org/10.2147/RRU.S71325

2016-07-18

Abstract:The potential influence of vasectomy being a risk factor for the development of prostate cancer is not a new concept, with more than 30 publications addressing the topic. Given the global frequency of vasectomy and the prevalence of prostate cancer, this subject justifiably deserves scrutiny. Several articles have claimed that vasectomy puts men at risk for future development of prostate cancer. We explore articles that have shown the contrary (no link), explore the studies' strengths and weaknesses, describe possible prostate cancer pathophysiologic mechanisms, and apply Bradford Hill criteria to help discern correlation with causation. The risk and interest of association of prostate cancer with vasectomy has waxed and waned over the last three decades. Based on our review, vasectomy remains a safe form of sterilization and does not increase prostate cancer risk.
Vasectomy and Risk of Prostate Cancer: A Systematic Review and Meta-analysis

Michael Baboudjian,Pawel Rajwa,Eric Barret,Jean-Baptiste Beauval,Laurent Brureau,Gilles Créhange,Charles Dariane,Gaëlle Fiard,Gaëlle Fromont,Mathieu Gauthé,Romain Mathieu,Raphaële Renard-Penna,Guilhem Roubaud,Alain Ruffion,Paul Sargos,Morgan Rouprêt,Guillaume Ploussard,Prostate Cancer Committee of the Association Française d'Urologie CC-AFU

DOI: https://doi.org/10.1016/j.euros.2022.04.012

2022-05-19

Abstract:Context: Previous reports have shown an association between vasectomy and prostate cancer (PCa). However, there exist significant discrepancies between studies and systematic reviews due to a lack of strong causal association and residual confounding factors such as prostate-specific antigen (PSA) screening. Objective: To assess the association between vasectomy and PCa, in both unadjusted and PSA screen-adjusted studies. Evidence acquisition: We performed a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses. The PubMed, Scopus, and Web of Science databases were searched in January 2022 for studies that analyzed the association between vasectomy and PCa. Evidence synthesis: A total of 37 studies including 16 931 805 patients met our inclusion criteria. A pooled analysis from all studies showed a significant association between vasectomy and any-grade PCa (odds ratio [OR] 1.23; 95% confidence interval [CI], 1.10-1.37; p < 0.001; I2 = 96%), localized PCa (OR 1.08; 95% CI, 1.06-1.11; p < 0.00001; I2 = 31%), or advanced PCa (OR 1.07; 95% CI, 1.02-1.13; p = 0.006; I2 = 0%). The association with PCa remained significant when the analyses were restricted to studies with a low risk of bias (OR 1.06; 95% CI, 1.02-1.10; p = 0.02; I2 = 48%) or cohort studies (OR 1.09; 95% CI, 1.04-1.13; p < 0.0001; I2 = 64%). Among studies adjusted for PSA screening, the association with localized PCa (OR 1.06; 95% CI, 1.03-1.09; p < 0.001; I2 = 0%) remained significant. Conversely, vasectomy was no longer associated with localized high-grade (p = 0.19), advanced (p = 0.22), and lethal (p = 0.42) PCa. Conclusions: Our meta-analysis found an association between vasectomy and any, mainly localized, PCa. However, the effect estimates of the association were increasingly close to null when examining studies of robust design and high quality. On exploratory analyses including studies, which adjusted for PSA screening, the association for aggressive and/or advanced PCa diminished. Patient summary: In this study, we found an association between vasectomy and the risk of developing localized prostate cancer without being able to determine whether the procedure leads to a higher prostate cancer incidence.
The Association Between Vasectomy and Prostate Cancer: A Systematic Review and Meta-analysis

Bimal Bhindi,Christopher J D Wallis,Madhur Nayan,Ann M Farrell,Landon W Trost,Robert J Hamilton,Girish S Kulkarni,Antonio Finelli,Neil E Fleshner,Stephen A Boorjian,R Jeffrey Karnes

DOI: https://doi.org/10.1001/jamainternmed.2017.2791

2017-09-01

Abstract:Importance: Despite 3 decades of study, there remains ongoing debate regarding whether vasectomy is associated with prostate cancer. Objective: To determine if vasectomy is associated with prostate cancer. Data sources: The MEDLINE, EMBASE, Web of Science, and Scopus databases were searched for studies indexed from database inception to March 21, 2017, without language restriction. Study selection: Cohort, case-control, and cross-sectional studies reporting relative effect estimates for the association between vasectomy and prostate cancer were included. Data extraction and synthesis: Two investigators performed study selection independently. Data were pooled separately by study design type using random-effects models. The Newcastle-Ottawa Scale was used to assess risk of bias. Main outcomes and measures: The primary outcome was any diagnosis of prostate cancer. Secondary outcomes were high-grade, advanced, and fatal prostate cancer. Results: Fifty-three studies (16 cohort studies including 2 563 519 participants, 33 case-control studies including 44 536 participants, and 4 cross-sectional studies including 12 098 221 participants) were included. Of these, 7 cohort studies (44%), 26 case-control studies (79%), and all 4 cross-sectional studies were deemed to have a moderate to high risk of bias. Among studies deemed to have a low risk of bias, a weak association was found among cohort studies (7 studies; adjusted rate ratio, 1.05; 95% CI, 1.02-1.09; P < .001; I2 = 9%) and a similar but nonsignificant association was found among case-control studies (6 studies; adjusted odds ratio, 1.06; 95% CI, 0.88-1.29; P = .54; I2 = 37%). Effect estimates were further from the null when studies with a moderate to high risk of bias were included. Associations between vasectomy and high-grade prostate cancer (6 studies; adjusted rate ratio, 1.03; 95% CI, 0.89-1.21; P = .67; I2 = 55%), advanced prostate cancer (6 studies; adjusted rate ratio, 1.08; 95% CI, 0.98-1.20; P = .11; I2 = 18%), and fatal prostate cancer (5 studies; adjusted rate ratio, 1.02; 95% CI, 0.92-1.14; P = .68; I2 = 26%) were not significant (all cohort studies). Based on these data, a 0.6% (95% CI, 0.3%-1.2%) absolute increase in lifetime risk of prostate cancer associated with vasectomy and a population-attributable fraction of 0.5% (95% CI, 0.2%-0.9%) were calculated. Conclusions and relevance: This review found no association between vasectomy and high-grade, advanced-stage, or fatal prostate cancer. There was a weak association between vasectomy and any prostate cancer that was closer to the null with increasingly robust study design. This association is unlikely to be causal and should not preclude the use of vasectomy as a long-term contraceptive option.
Vasectomy and risk of prostate cancer: A Mendelian randomization study and confounder analysis

Huajie Di,Yi Wen

DOI: https://doi.org/10.1002/pros.24646

Abstract:Background: Previous reports have shown a potential causal impact of vasectomy on prostate cancer (PCa). The objective of this study was to investigate the association between vasectomy and PCa, while evaluating the influence of confounding factors such as prostate-specific antigen (PSA) screening and body mass index (BMI). Methods: Mendelian randomization (MR) study using summary statistics from genome-wide associations of vasectomy (462,933 European ancestry), ever had PSA test (200,410 European ancestry), time since last PSA test (46,104 European ancestry), BMI (152,893 European males) and PCa (79,148 cases, 61,106 controls, European ancestry). This study was conducted using summary statistic data from large, previously described cohorts. Data analyses were conducted from November 2022 to June 2023. Results: Genetic liability to vasectomy was not associated with PCa (OR = 0.07, 95% CI: 2.95 × <math altimg="urn:x-wiley:02704137:media:pros24646:pros24646-math-0001" wiley:location="equation/pros24646-math-0001.png" xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mrow><mo>\unicode{x000D7}</mo></mrow></mrow></math> 10-3 , 1.54, p = 0.09). Genetic liability to vasectomy was not associated with ever had PSA test (OR = 1.08, 95% CI: 0.49-2.39, p = 0.83) and time since last PSA test (OR = 2.49, 95% CI: 0.71-8.79, p = 0.16). After controlling for PSA test and BMI, there remains no causal relationship between vasectomy and PCa risk (OR = 5.56 × <math altimg="urn:x-wiley:02704137:media:pros24646:pros24646-math-0002" wiley:location="equation/pros24646-math-0002.png" xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mrow><mo>\unicode{x000D7}</mo></mrow></mrow></math> 10-4 , 95% CI: 7.29 × <math altimg="urn:x-wiley:02704137:media:pros24646:pros24646-math-0003" wiley:location="equation/pros24646-math-0003.png" xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mrow><mo>\unicode{x000D7}</mo></mrow></mrow></math> 10-8 , 4.24, p = 0.10). The reverse MR results showed a weak association between PCa and vasectomy patients (OR = 1.00, 95% CI: 1.0003-1.0033, p = 0.02). Conclusion: Based on the available evidence from MR analysis, the current findings did not support vasectomy being a risk factor for PCa. Further work is required to provide additional confirmation and validation of the potential link.
Vasectomy and the risk of prostate cancer in a prospective US Cohort: Data from the NIH-AARP Diet and Health Study

M T Davenport,C A Zhang,J T Leppert,J D Brooks,M L Eisenberg

DOI: https://doi.org/10.1111/andr.12570

Andrology

Abstract:Background: Several studies have linked vasectomy with the risk of prostate cancer; however, this association has been attributed to selection bias. Since vasectomy is a common and effective form of contraception, these implications are significant. Therefore, we sought to test this association in a large observational cohort. Objective: To evaluate the potential association between prior vasectomy and the risk of developing prostate cancer. Materials and methods: We evaluated the relationship between vasectomy and prostate cancer in the NIH-AARP Diet and Health Study. Of the 111,914 men, prostate cancer was identified in 13,885 men and vasectomies were performed in 48,657. We used multivariate analysis to examine the relationship between prostate cancer and vasectomy. We also performed propensity score-adjusted and propensity score-matched analysis. Results: Men utilizing vasectomy were more likely to be ever married, fathers, educated, white, and screened for prostate cancer. During 4,251,863 person-years of follow-up, there was a small association between vasectomy and incident prostate cancer with a hazard ratio of 1.05 (95% CI, 1.01-1.11). However, no significant association was found when looking separately at prostate cancer by grade or stage. Conclusions were similar when using propensity adjustment and matching. Importantly, a significant interaction between vasectomy and PSA screening was identified. Discussion: Estimates of the association between vasectomy and prostate cancer are sensitive to analytic method underscoring the tenuous nature of the connection. Given the differences between men who do and do not utilize vasectomy, selection bias appears likely to explain any identified association between vasectomy and prostate cancer. Conclusions: With over 20 years of follow-up, no convincing relationship between vasectomy and prostate cancer of any grade was identified.
Vasectomy and risk of prostate cancer: population based matched cohort study

Madhur Nayan,Robert J Hamilton,Erin M Macdonald,Qing Li,Muhammad M Mamdani,Craig C Earle,Girish S Kulkarni,Keith A Jarvi,David N Juurlink,Canadian Drug Safety and Effectiveness Research Network (CDSERN)

DOI: https://doi.org/10.1136/bmj.i5546

2016-11-03

BMJ

Abstract:Objective: To determine the association between vasectomy and prostate cancer, adjusting for measures of health seeking behaviour. Design: Population based matched cohort study. Setting: Multiple validated healthcare databases in Ontario, Canada, 1994-2012. Participants: 326 607 men aged 20 to 65 who had undergone vasectomy were identified through physician billing codes and matched 1:1 on age (within two years), year of cohort entry, comorbidity score, and geographical region to men who did not undergo a vasectomy. Main outcomes measures: The primary outcome was incident prostate cancer. Secondary outcomes were prostate cancer related grade, stage, and mortality. Results: 3462 incident cases of prostate cancer were identified after a median follow-up of 10.9 years: 1843 (53.2%) in the vasectomy group and 1619 (46.8%) in the non-vasectomy group. In unadjusted analysis, vasectomy was associated with a slightly increased risk of incident prostate cancer (hazard ratio 1.13, 95% confidence interval 1.05 to 1.20). After adjustment for measures of health seeking behaviour, however, no association remained (adjusted hazard ratio 1.02, 95% confidence interval 0.95 to 1.09). Moreover, no association was found between vasectomy and high grade prostate cancer (adjusted odds ratio 1.05, 95% confidence interval 0.67 to 1.66), advanced stage prostate cancer (adjusted odds ratio 1.04, 0.81 to 1.34), or mortality (adjusted hazard ratio 1.06, 0.60 to 1.85). Conclusion: The findings do not support an independent association between vasectomy and prostate cancer.
Vasectomy and Risk of Prostate Cancer in a Screening Trial

Jonathan Shoag,Oleksander Savenkov,Paul J Christos,Sameer Mittal,Joshua A Halpern,Gulce Askin,Daniel Shoag,Ron Golan,Daniel J Lee,Padraic O'Malley,Bobby Najari,Brian Eisner,Jim C Hu,Douglas Scherr,Peter Schlegel,Christopher E Barbieri

DOI: https://doi.org/10.1158/1055-9965.EPI-16-0776

Abstract:Background: Vasectomy has been implicated as a risk factor for prostate cancer in multiple epidemiologic studies over the past 25 years. Whether this relationship is causal remains unclear. This study examines the association between vasectomy and prostate cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, which randomized men to usual care or annual prostate cancer screening.Methods: We performed a retrospective analysis of 13-year screening and outcomes data from the PLCO trial. Multivariable Cox proportional hazards regression stratified by study arm and age at vasectomy was performed.Results: There was an increased risk of prostate cancer in men who had undergone a vasectomy and were randomized to the usual care arm of the study (adjusted HR, 1.11; 95% confidence interval, 1.03-1.20; P = 0.008). There was no association between vasectomy and diagnosis of prostate cancer in men randomized to the prostate cancer screening arm. Only men undergoing vasectomy at an older age in the usual care arm of the study, but not the prostate cancer screening arm, were at increased risk of being diagnosed with prostate cancer.Conclusions: Vasectomy was not associated with prostate cancer risk among men who were screened for prostate cancer as part of a clinical trial, but was associated with prostate cancer detection in men receiving usual care.Impact: The positive association between vasectomy and prostate cancer is likely related to increased detection of prostate cancer based on patterns of care rather than a biological effect of vasectomy on prostate cancer development. Cancer Epidemiol Biomarkers Prev; 26(11); 1653-9. ©2017 AACR.
Vasectomy and Prostate Cancer Risk: A 38-Year Nationwide Cohort Study

Anders Husby,Jan Wohlfahrt,Mads Melbye

DOI: https://doi.org/10.1093/jnci/djz099

2020-01-01

Abstract:Background: A man's risk of prostate cancer has been linked to his prior reproductive history, with low sperm quality, low ejaculation frequency, and a low number of offspring being associated with increased prostate cancer risk. It is, however, highly controversial whether vasectomy, a common sterilization procedure for men, influences prostate cancer risk. Methods: We established a cohort of all Danish men (born between 1937 and 1996) and linked information on vasectomy, doctor visits, socioeconomic factors, and cancer from nationwide registries using unique personal identification numbers. Incidence risk ratios for prostate cancer by time since vasectomy and age at vasectomy during the follow-up were estimated using log-linear Poisson regression. Results: Overall, 26 238 cases of prostate cancer occurred among 2 150 162 Danish men during 53.4 million person-years of follow-up. Overall, vasectomized men had an increased risk of prostate cancer compared with nonvasectomized men (relative risk = 1.15, 95% confidence interval = 1.10 to 1.20). The increased risk of prostate cancer following vasectomy persisted for at least 30 years after the procedure and was observed regardless of age at vasectomy and cancer stage at diagnosis. Adjustment for the number of visits to the doctor and socioeconomic factors did not explain the association. Conclusions: Vasectomy is associated with a statistically significantly increased long-term risk of prostate cancer. The absolute increased risk following vasectomy is nevertheless small, but our finding supports a relationship between reproductive factors and prostate cancer risk.
Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC)

Karl Smith,Byrne,Jose Maria Castaño,Maria Dolores Chirlaque,Hans Lilja,Antonio Agudo,Eva Ardanaz,Miguel Rodríguez-Barranco,Heiner Boeing,Rudolf Kaaks,Kay-Tee Khaw,Nerea Larrañaga,Carmen Navarro,Anja Olsen,Kim Overvad,Aurora Perez-Cornago,Sabine Rohrmann,Maria José Sánchez,Anne Tjønneland,Konstantinos K Tsilidis,Mattias Johansson,Elio Riboli,Timothy J Key,Ruth C Travis

DOI: https://doi.org/10.1200/JCO.2016.70.0062

2017-04-20

Abstract:Purpose Vasectomy is a commonly used form of male sterilization, and some studies have suggested that it may be associated with an increased risk of prostate cancer, including more aggressive forms of the disease. We investigated the prospective association of vasectomy with prostate cancer in a large European cohort, with a focus on high-grade and advanced-stage tumors, and death due to prostate cancer. Patients and Methods A total of 84,753 men from the European Prospective Investigation into Cancer and Nutrition (EPIC), aged 35 to 79 years, provided information on vasectomy status (15% with vasectomy) at recruitment and were followed for incidence of prostate cancer and death. We estimated the association of vasectomy with prostate cancer risk overall, by tumor subtype, and for death due to prostate cancer, using multivariable-adjusted Cox proportional hazards models. Results During an average follow-up of 15.4 years, 4,377 men were diagnosed with prostate cancer, including 641 who had undergone a vasectomy. Vasectomy was not associated with prostate cancer risk (hazard ratio [HR], 1.05; 95% CI, 0.96 to 1.15), and no evidence for heterogeneity in the association was observed by stage of disease or years since vasectomy. There was some evidence of heterogeneity by tumor grade ( P = .02), with an increased risk for low-intermediate grade (HR, 1.14; 95% CI, 1.01 to 1.29) but not high-grade prostate cancer (HR, 0.83; 95% CI, 0.64 to 1.07). Vasectomy was not associated with death due to prostate cancer (HR, 0.88; 95% CI, 0.68 to 1.12). Conclusion These findings from a large European prospective study show no elevated risk for overall, high-grade or advanced-stage prostate cancer, or death due to prostate cancer in men who have undergone a vasectomy compared with men who have not.
Vasectomy Not Associated with Prostate Cancer: A Meta-analysis

Ling-feng Tang,Hui Jiang,Xue-jun Shang,Lian-ming Zhao,Quan Bai,Kai Hong,De-feng Liu,Jian-ming Liu,Ren-pei Yuan,Qian Chen,Lu-lin Ma

DOI: https://doi.org/10.13263/j.cnki.nja.2009.06.022

2009-01-01

Abstract:OBJECTIVE:To evaluate the association between vasectomy and prostate cancer. METHODS:We searched comprehensively the databases, CBMDisc, CMCC, CMAC, CNKI (from 1978 to January 6, 2009), and PubMed (from 1965 to January 6, 2009) using the key words "vasectomy" and "prostate cancer", screened the retrieved literature according to the inclusion and exclusion criteria, performed a Meta-analysis with the software RevMan 4.2 after identification of the relevant data, and calculated the overall pooled OR (95% CI) as well as that of the association of prostate cancer with <20 and > or =20 yr vasectomy. RESULTS:A total of 20 088 cases and 232 506 controls in 27 reports (7 cohort and 20 case-control studies) were included in this investigation. The overall pooled OR (95% CI) was 1.10 (0.97-1.24), and those of <20 and > or =20 yr vasectomy were 0.94 (0.83-1.06) and 1.05 (0.90-1.23), respectively. CONCLUSION:No existing literature show any positive association between vasectomy and prostate cancer.
Insights from Immunomics and Metabolomics on the Associations Between Prostatic Diseases and Coronavirus Disease 2019

Feixiang Yang,Peng Guo,Kun Wang,Xiangyu Zhang,Zhehao Hu,Qiyue Lou,Qintao Ge,Yiding Chen,Chaozhao Liang,Jialin Meng

DOI: https://doi.org/10.1016/j.prnil.2024.07.003

IF: 3.07

2024-01-01

Prostate International

Abstract:Background: The causal associations and potential mechanisms between prostatic diseases, the predominant male urological disorders, and the course of COVID-19 remain unclear. Methods: A two-sample Mendelian randomization (MR) analysis was performed to evaluate causal associations between prostate cancer, benign prostatic hyperplasia, and prostatitis and different COVID19 outcomes (SARS-CoV-2 infection, hospitalized COVID-19, and severe COVID-19). Reverse MR, linkage disequilibrium score regression, and Bayesian colocalization analyses were subsequently performed to strengthen the identified causal relationships. Furthermore, immunome- and metabolome-wide MR analysis was conducted to prioritize COVID-19-associated immune characteristics and metabolites. Twostep MR analysis was performed to evaluate the mediating effects of the immunome and metabolome on the associations between prostatic diseases and COVID-19. Results: Genetically predicted prostatic diseases were not causally associated with severe COVID-19, while prostatitis was suggested to be an independent risk factor for SARS-CoV-2 infection (odds ratio (OR) = 1.11, 95% confidence interval (CI) 1.01 to 1.23; P = 0.03). Multiple sensitivity tests verified the reliability of the established causal relationships. Dozens of blood immune and metabolic features were identified to reveal the immune and metabolic profiles of different COVID-19 courses. Moreover, PDL-1 on monocyte was found to mediate the interaction between prostatitis and SARS-CoV-2 infection, with a mediation proportion of 9.2%. Conclusion: Our study identified the causal relationships of prostatic diseases with COVID-19 and suggested pathways explaining these associations through alterations in the blood immunome and metabolome. (c) 2024 The Asian Pacific Prostate Society. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
[Vasectomy does not increase the risk of prostate cancer in Chinese men: A meta-analysis]

Wen-qing Lian,Fei Luo,Peng-liang Chen,Shen-fan Wang,Bo-wei Zhou,Shan-chao Zhao

Abstract:Objective: To investigate the correlation of vasectomy with the risk of prostate cancer in Chinese men. Methods: We systematically searched the databases CNKI, VIP, Wanfang, PubMed, Embase, and Cochrane Library for the literature relating the relationship between vasectomy and the risk of prostate cancer in Chinese males up to December 2014. According to the inclusion and exclusion criteria, two investigators independently selected the eligible publications, evaluated their quality, and extracted relevant information, followed by a meta-analysis with the software STATA 12.0. Results: Nine studies were included in the analysis involving 1 202 cases of prostate cancer and 4,496 controls. Random-effect model analysis revealed no statistically significant correlation between vasectomy and the risk of prostate cancer (OR = 1.05; 95% CI 0.62-1.79), with an obvious heterogeneity (P < 0.001, I2 = 85.7%). No significant publication bias was found among the included studies (Egger, P = 0.824; Begg, P = 0.348). Conclusion: The results of our meta-analysis do not support the association of vasectomy with the increased risk of prostate cancer in Chinese population.
The Effect of Vasectomy Reversal on Prostate Cancer Risk: International Meta-Analysis of 684,660 Vasectomized Men

Sean Randall,James Boyd,Emma Fuller,Caroline Brooks,Carole Morris,Craig C Earle,Anna Ferrante,Rachael Moorin,James Semmens,C D'Arcy J Holman

DOI: https://doi.org/10.1016/j.juro.2018.03.005

Abstract:Purpose: Evidence of the effect of vasectomy on prostate cancer is conflicting with the issue of detection bias a key criticism. We examined the effect of vasectomy reversal on prostate cancer risk in a cohort of vasectomized men. Evidence of a protective effect would be consistent with a harmful effect of vasectomy on prostate cancer risk while nullifying the issue of detection bias. Materials and methods: Data were sourced from a total of 5 population level linked health databases in Australia, Canada and the United Kingdom. Cox proportional hazards regression analysis was used to compare the risk of prostate cancer in 9,754 men with vasectomy reversal to the risk in 684,660 with vasectomy but no reversal. Data from each jurisdiction were combined in a meta-analysis. Results: The combined analysis showed no protective effect of vasectomy reversal on the incidence of prostate cancer compared to that in men with vasectomy alone (HR 0.92, 95% CI 0.70-1.21). Conclusions: These results align with those of previous studies showing no evidence of a link between vasectomy and prostate cancer.

Can there be consensus on whether vasectomy is a prostate cancer risk factor?

Vasectomy: potential links to an increased risk of aggressive prostate cancer?

Vasectomy and prostate cancer risk: a meta-analysis of prospective studies

Association between vasectomy and risk of prostate cancer: a meta-analysis

Vasectomy and prostate cancer risk: a meta-analysis of cohort studies

Vasectomy and the risk of prostate cancer: a meta-analysis of cohort studies

Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study

Vasectomy and risk of prostate cancer: a systematic review and meta-analysis of cohort studies

Vasectomy and prostate cancer risk: a historical synopsis of undulating false causality

Vasectomy and Risk of Prostate Cancer: A Systematic Review and Meta-analysis

The Association Between Vasectomy and Prostate Cancer: A Systematic Review and Meta-analysis

Vasectomy and risk of prostate cancer: A Mendelian randomization study and confounder analysis

Vasectomy and the risk of prostate cancer in a prospective US Cohort: Data from the NIH-AARP Diet and Health Study

Vasectomy and risk of prostate cancer: population based matched cohort study

Vasectomy and Risk of Prostate Cancer in a Screening Trial

Vasectomy and Prostate Cancer Risk: A 38-Year Nationwide Cohort Study

Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC)

Vasectomy Not Associated with Prostate Cancer: A Meta-analysis

Insights from Immunomics and Metabolomics on the Associations Between Prostatic Diseases and Coronavirus Disease 2019

[Vasectomy does not increase the risk of prostate cancer in Chinese men: A meta-analysis]

The Effect of Vasectomy Reversal on Prostate Cancer Risk: International Meta-Analysis of 684,660 Vasectomized Men